In ovarian cancer xenograft models, NEAT1 knockdown suppresses paclitaxel and cisplatin resistance, thereby reducing tumor growth, supporting the potential of NEAT1 silencing as a chemosensitization strategy [453, 454]. This evidence concerns the gene NEAT1 and ovarian carcinoma.